DENVER, CO -- (Marketwire) -- 10/06/10 -- The Denver, Colorado law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that a class action securities fraud lawsuit has been filed on behalf of purchasers of AspenBio Pharma, Inc. (NASDAQ: APPY) common stock during the period between February 22, 2007 and July 19, 2010 (the "Class Period"). AspenBio Pharma, Inc. is a small Colorado bio-pharmaceutical company focusing on the discovery, development, manufacture, and marketing of products.
If you wish to serve as a lead plaintiff, you must seek such an appointment with the court no later than November 30, 2010. A "lead plaintiff" directs the litigation and participates in important decisions including whether to accept a settlement offer and how much of a settlement to accept for the class in the action. The lead plaintiff here will be selected from among applicants claiming the largest loss from investment in the company during the Class Period. Any member of the putative class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you wish to discuss the action, the lead plaintiff process, or have any questions concerning your rights or interests in the litigation, please contact Jeffrey A. Berens, Esq. at (888) 300-3362 x302, (303) 861-1764, or via email at firstname.lastname@example.org.
Dyer & Berens LLP has significant expertise in prosecuting investor class actions. The firm's extensive experience in securities litigation, particularly in cases brought under the Private Securities Litigation Reform Act, has contributed to the recovery of hundreds of millions of dollars for aggrieved investors. For more information about the firm, please go to www.DyerBerens.com.